Deng Yayuan, Shi Mengjia, Yi Lin, Naveed Khan Muhammad, Xia Zhijia, Li Xiaosong
The First College of Clinical Medicine, Chongqing Medical University, Chongqing, China.
Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Heliyon. 2024 Aug 30;10(17):e37060. doi: 10.1016/j.heliyon.2024.e37060. eCollection 2024 Sep 15.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by producing remarkable clinical outcomes for patients with various cancer types. However, only a subset of patients benefits from immunotherapeutic interventions due to the primary and acquired resistance to ICIs. Myeloid-derived suppressor cells (MDSCs) play a crucial role in creating an immunosuppressive tumor microenvironment (TME) and contribute to resistance to immunotherapy. V-domain Ig suppressor of T cell activation (VISTA), a negative immune checkpoint protein highly expressed on MDSCs, presents a promising target for overcoming resistance to current ICIs. This article provides an overview of the evidence supporting VISTA's role in regulating MDSCs in shaping the TME, thus offering insights into how to overcome immunotherapy resistance.
免疫检查点抑制剂（ICI）通过为各种癌症类型的患者带来显著的临床疗效，彻底改变了癌症治疗方式。然而，由于对ICI的原发性和获得性耐药，只有一部分患者能从免疫治疗干预中获益。髓源性抑制细胞（MDSC）在创建免疫抑制性肿瘤微环境（TME）中起关键作用，并导致对免疫治疗的耐药。T细胞活化V结构域免疫球蛋白抑制因子（VISTA）是一种在MDSC上高度表达的负性免疫检查点蛋白，是克服对当前ICI耐药的一个有前景的靶点。本文概述了支持VISTA在调节MDSC以塑造TME中作用的证据，从而为如何克服免疫治疗耐药提供见解。
